Bank Of New York Mellon Corp Tcr2 Therapeutics Inc. Transaction History

Bank Of New York Mellon Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.83 - $1.44 $10,586 - $18,367	12,755 New	12,755 $12,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $191,408 - $266,702	-90,715 Reduced 87.67%	12,755 $37,000
Q1 2022 May 11, 2022	SELL	$2.4 - $4.71 $18,943 - $37,176	-7,893 Reduced 7.09%	103,470 $285,000
Q4 2021 Feb 11, 2022	BUY	$4.58 - $8.34 $18,416 - $33,535	4,021 Added 3.75%	111,363 $519,000
Q3 2021 Nov 12, 2021	SELL	$8.44 - $18.35 $72,162 - $156,892	-8,550 Reduced 7.38%	107,342 $913,000
Q2 2021 Aug 11, 2021	SELL	$16.41 - $24.71 $150,775 - $227,035	-9,188 Reduced 7.35%	115,892 $1.9 Million
Q1 2021 May 13, 2021	SELL	$20.38 - $34.07 $5,808 - $9,709	-285 Reduced 0.23%	125,080 $2.76 Million
Q4 2020 Feb 09, 2021	BUY	$19.0 - $32.63 $906,091 - $1.56 Million	47,689 Added 61.39%	125,365 $3.88 Million
Q3 2020 Nov 12, 2020	BUY	$13.1 - $20.69 $302,426 - $477,649	23,086 Added 42.29%	77,676 $1.58 Million
Q2 2020 Aug 12, 2020	BUY	$6.51 - $16.85 $85,378 - $220,987	13,115 Added 31.62%	54,590 $838,000
Q4 2019 Feb 14, 2020	BUY	$12.17 - $17.88 $151,054 - $221,926	12,412 Added 42.71%	41,475 $592,000
Q3 2019 Nov 07, 2019	BUY	$10.15 - $19.53 $294,989 - $567,600	29,063 New	29,063 $436,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.